Helicobacter pylori is necessary, because of high prevalence of the infection (25 to 90%). Moreover, this bacteria has been classified as a grade I carcinogen by WHO since 1994. Catalase, an important enzyme in the virulence of H. pylori, could be a suitable candidate for vaccine design because it is highly conserved, which is important for the survival of H. pylori; it is expressed in high level and it is exposed on the surface of the bacteria. In this study, we designed epitope-based vaccine for catalase specific regions of H. pylori by means of immunobioinformatic tools. H. pylori (26695) catalase has been compared with human catalase in order to select specific regions. Afterwards, epitopes of catalase were determined by propred software. Among predicted epitopes, three epitopes were selected including, MVNKDVKQTT, VLLQSTWFL and FHPFDVTKI. Three candidates out of 51catalase antigen epitopes had the highest score for reactivating with MHC II MHC in propred software. The candidate epitopes for vaccine design should be rather a composition of considering epitopes: MVNKDVKQTTKKVLLQSTWFLKKFHPFDVTKI. In this manner, 39 of 51 alleles of MHC class ІІ were involved and stimulated T-cell responses. We believe prediction of catalase epitopes by the immunoinformatics tools would be valuable for developing new immuoprophylatic strategy against H. pylori infection.
INTRODUCTION

Importance of epitopes and bioinformatics tools
New genome analysis tools based on bioinformatics and immunoinformatics technologies help us to select the correct antigen or epitope of interest directly from the genomes of pathogens in order to design a vaccine (De Groot et al., 2001; Moise et al., 2008; Zhou et al., 2009) .
To develop an epitope-based vaccine, it is necessary to detect immunostimulatory patterns. Protective immune responses may be generated based on a single immunedominant or more epitopes (De Groot and Berzofsky, 2004) . Thus, it is important to choose epitopes derived *Corresponding author. E-mail: ghasemian@med.mui.ac.ir. Tel: 983117922469. Fax: 983116688597. from conserved peptide sequences (Khan et al., 2006) . T-cell responses are stimulated by the presence of short peptides bound on the surface of antigen presenting cells and binding to major histocompatibility complex (MHC) molecules (De Groot and Berzofsky, 2004) .
It is important to consider the protein antigen sequences that function at T-cell epitopes for successful vaccine formulations (Sette et al., 2001; Brusic and August, 2004; Khan et al., 2006) . These tools allow us to decide on epitopes or sub-sequences of proteins that interface with the T-cells of the host and predict the MHC binder (De Groot and Berzofsky, 2004) . Such tools let the scanning of genome-derived protein sequences for T-cell epitopes and the 8 to 10 mer peptides that bind to MHC and interact with the T cell receptor, stimulate T-cell response. These epitopes prediction tools are proved to be very useful, since they significantly reduce the time and effort implicated in screening probable epitopes, mainly for pathogens that do not currently present available vaccines and still needs to be further investigated (De Groot and Berzofsky, 2004; Shi et al., 2007; Moise et al., 2008; Zhou et al., 2009) . A usual epitope-based vaccine build contains epitopes inserted repeatedly in the construct, with or without intervening spacer amino acids (De Groot et al., 2001; Zhou et al., 2009; Liu et al., 2004) . The advantages of this kind of vaccine are: stimulating specific immune responses against conserved sequences, increasing safety and increased strength and extent by the application of practically engineer epitopes (Shi et al., 2007) .
Selection of candidate protein sequences can be followed by the use of computerized (in silico) software to recognize regions of the proteins that are probable immunogenic. These peptides, representing the epitopes, could be synthesized and their ability to stimulate immune response could be monitored, in vitro, by using prepared T-cells from patients (De Groot and Berzofsky, 2004) .
Helicobacter pylori infection and antigens
Several microbial agents that cause considerably high rates of mortality and diseases are still waiting for vaccines. One of them is Helicobacter pylori (H. pylori).
There are several problems caused by H. pylori infection including: (1) the eradication is not well satisfied; (2) high re-infection rates of patients; (3) high amount of drug dose for treatment; (4) antibiotics resistance (5) high prevalence (80 to 90%) of infected populations in developing countries (Farshad et al., 2009; Ruggiero et al., 2003; Graham, 2000) ; (6) and classification as a grade 1 carcinogen by WHO (Radcliff et al., 1997; Schistosomes, 1994) .
An antigen should have important features to be determined as a vaccine candidate: it should be expressed at the surface abundantly, in order to be easily recognized by immune system, and the sequences should be well conserved and represented as a key virulence factors (Ruggiero et al., 2003) . Most of the vaccine of H. pylori antigen investigated in mouse model was whole cell of bacteria, urease, heat shock protein, vacuolating cytotoxin and recently, catalase (Ruggiero et al., 2003; Liu et al., 2004) .
Catalase could be a suitable candidate for vaccine design. It has very conserved domains, it is expressed in high levels (1% of the cell's total protein) (Harris et al., 2002) , it is an important factor for survival of H. pylori in an environment rich in toxic oxygen species, found in both the cytosol and the periplasmic space and therefore, it is exposed on bacterial surface and could be easily identified by the immune system (Ramarao et al., 2000; Harris et al., 2002; Radcliff et al., 1997; Guy et al. 2005; Hazell et al., 1991) .
Immunity
The mechanisms of defense against H. pylori infection are uncertain. Despite strong immune responses, the infection remains for a long time. It is suggested that the H. pylori can evade both innate and adaptive immune responses. The immune systems are triggered by H. pylori in nature but the responses are not good enough to eliminate this pathogen (Shi et al., 2007; Baldari et al., 2005) . There are increasing evidences to hold up that MHCII restricted CD4+ cells play an essential role in defense mechanisms, more than antibodies. A successful immunotherapeutic or immunoprophylactic plan against H. pylori should include CD4+ Th cell epitopes (Shi et al., 2007; Ermak et al., 1998; Pappo et al., 1999) . Therefore, we believe that stimulating the immune response by vaccine, compared with that of the nature infection could be more effective against H. pylori (Shi et al., 2007) . In this study, we decided to design epitopebased vaccine according to immunobioinformatic tools for the catalase of H. pylori.
MATERIALS AND METHODS
Data collection and identification of specific sequences
Complete sequence of H. pylori 26695 catalase were acquired from NCBI; accession code, NP-207669, 505 amino acid and used to identify the specific sequences of catalase in H. pylori (26695) and were compared with human catalase (NCBI, accession code: NP-001743) and other strains of H. pylori using blast. The sequence of H. pylori 26695 catalase had 98 to 100% similarity with the catalase of other H. pylori strains (25 strains) which are sequenced in NCBI such as H. pylori P12, G27, shi470, J99, ss1, 51,F32, 35A, 908, India 7, etc.
Prediction of T-cell epitopes
Several T-cell epitopes that are identified by more than one MHC and recognized by more than one T-cell clone are called 'promisecuous 'epitopes (De Groot et al., 2001; Khan et al., 2006) . Different prediction methods according to biological information are considered for epitopes. In this study, we chose Propred software for prediction promiscuous T-cell epitopes (Singh and Raghava, 2001; Contini et al., 2008; Saltini et al., 2008) . The propred web interface allows users to predict MHC class II binding regions in antigen sequence. 51 MHC class II epitope-mapping matrices were developed at propred; therefore, it is helpful for the user in locating promiscuous or allele specific binding regions in a query antigen. The peptides (epitopes) predicted in this software, are nanomer. In each nanomer, there is an anchor or a starting residue. The 51 alleles of MHC class II in propred software were as following : DRB1:0101,0102,0301,0305,0306,0307,0308,0309,0311,0401,040 2,0404,0405,0408,0410,0421,0423,0426,0701,0703,0801,0802,080 4, 0806,0813,0817,1101 0806,0813,0817, ,1102 0806,0813,0817, ,1104 0806,0813,0817, ,1106 0806,0813,0817, ,1107 0806,0813,0817, ,1114 0806,0813,0817, ,1120 0806,0813,0817, ,1121 0806,0813,0817, ,112 8,1301 0806,0813,0817, ,1302 0806,0813,0817, ,1304 0806,0813,0817, ,1305 0806,0813,0817, ,1307 0806,0813,0817, ,1311 0806,0813,0817, ,1321 0806,0813,0817, ,1322 0806,0813,0817, ,1323 0806,0813,0817, ,1327 0806,0813,0817, ,1328 0806,0813,0817, ,150 1,1502 0806,0813,0817, ,1506 :0101 ,0105 .
The propred software displayed predicted binders as blue colored region and P1 anchor or the starting residue of each predicted binding frame as red colored. This illustration is useful to highlight the locating promiscuous binding regions (Table 1) .
RESULTS
In this study, we selected three epitopes from unique specific and specific regions ( Table 1 ). The first epitope was chosen from 1 to 8, the second epitope from 32 to 44 and the third epitope from 267 to 288 regions of H. pylori catalase (Table2).
Of the 51 epitopes, the selected epitopes had the highest score for reactivating MHC class ІІ in Propred software ( Table 3 ). The first epitope (MVNKDVKQTT) contained 26, the second (VLLQSTWFL) contained 21 and the third (FHPFDVTKI) contained 16 alleles of the 51 MHCII (Table2).
According to blast with human catalase (NCBI, accession code: NP-001743), our result showed that the unique specific regions contained eight amino acids of the initial region from N-terminal domain (MVNKDVKQ) and 19 amino acids of the final region from C-terminal domain (QKMMKDMHGKDMHHTKKKK). Other regions (shown as yellow boxes) were specific ( Figure 1) as follows: sequences from 10 to 20 (TAFGAPVWDDN); 32 to 44(LLQSTWFLEKLAA); 209 to 243(ERFWVKFHFHT-MQGVKHLTNEEAAEVRKYDPDS); 267 to 288 (PEEDA-KKYRFHPFDVTKIWYLQ); 372 to 381(MQNGYYGSLO); 421-431(DDSDYYTQPG); [428] [429] [430] [431] [432] [433] [434] [435] [436] [437] .
DISCUSSION
Prevalence of H. pylori infection is from 25% in developed countries to more than 90% in developing areas. H. pylori is a major cause of gastric carcinoma and lymphoma (Safaei et al., 2008; Rashidi and Ghasemian, 2005; Safaei et al., 2005; Mojtahedi et al., 2007; Safaei et al., 2010) .
Therapeutic vaccines against H. pylori, which have been assayed so far, are whole bacteria lysate, recombinant subunit antigen vaccines and DNA vaccines but no major advance has been achieved (Zhou et al., 2009) .
CD4 + T-cells play important roles in producing protective immunity (Shi et al., 2007) . Therefore, prediction antigenic epitopes in the context of MHC class ІІ molecules expressed on APC (antigen presenting cell) recognized by CD4 + T-cells can be use as a suitable tool for vaccination.
Catalase is a highly conserved enzyme, important for survival of the organism. There is 98 to 100% similarity between catalase of all Helicobacter species. This enzyme is expressed in high level and it is exposed on the surface of bacteria; therefore, it is a suitable antigen candidate for epitope vaccine evaluation (Radcliff et al., 1997) . Therefore, in this study, we designed epitope vaccine for H. pylori catalase with Propred software. The suggested epitope should be rather a composition of selected three epitopes: MVNKDVKQTTKKVLLQST-WFLKKFHPFDVTKI. This epitope involved 39 out of 51 alleles of MHC class ІІ and it stimulated T-cell responses. Lysines (KK) that is located between epitopes have some Rashidi et al. 8897 advantages: (1) cathepsine B, a protease that has role in processing antigens for presentation by MHC II, considers KK as a target; (2) it is possible that a new epitope is formed from linkage of some epitopes; therefore, lysines (KK) are an avoiding factor for this undesired event (Zhou et al., 2009 ). Guy et al. (2005) hypothesized four short fragments in N-terminal domain of H. pylori catalase (N1, N2, N3 and N4) and three short fragments in C-terminal domain which have shown a very low degree of sequence similarity with the human enzyme and can be introduced as specific regions for H. pylori protein. Our selected epitopes located in N1, N2 and N4 region was based on Guy's study. The first epitope was chosen from the amino acid residue of 1 to 20 which is the specific region of N1, the second epitope was from the amino acid residue of 30 to 44 which is the specific region of N2 and the third epitope was from the amino acid residue of 267 to 288 which is the specific region of N4 (Guy et al., 2005) . Sequences 10 to 20, 372 to 381, 421 to 431and 428 to 437 are specific regions and 490 to 505 is the unique specific region according to blast (Figure 1 ). But there was no epitopes in them according to Propred software and could not be selected as a vaccine candidate.
In the unique specific and specific sequences of H. pylori catalase, 1 to 10, 32 to 44, 267 to 288, 209 to 243, MVNKDVKQTT, VLLQSTWFL, FHPFDVTKI, VKHLT-NEEA and WVKFHFHTM epitopes were located (Table  3) .
Our first epitope MVNKDVKQTT covered 26 alleles. The first epitope presented a high score (with ranking 1 to 3 among all of the scores in the epitopes) in the reaction with the following alleles: 0301, 0306, 0307, 0311, 0402, 0801, 0802, 0804, 0806, 0817, 1102, 1107, 1114, 1121, 1301, 1322, 1323, 1327 and 1328. Among the selected epitopes, the first one was the only one which could alone react with the alleles: 0301, 0305, 0309, 0801, 0802, 0804, 0806 and 0817, also, the MVNKDVKQTT reacted with alleles 0305, 0309, 0813, 1120 and 1302 and presented acceptable scores.
The second epitope (VLLQSTWFL) covered 21 alleles and in the reaction with six alleles (0102, 0402, 0410, 1301, 1327 and 1328), it presented a high score. It is the only epitope that reacted with 0102, for 0410 to have a high score among all the other epitopes. It also presented acceptable scores in other alleles.
The third one (FHPFDVTKI) contained 16 alleles. It scored high in the reaction with some alleles : 0101, 0408, 0701, 0703 and 1502. It is the only epitope that reacted with 0101, 0408, 0701 and 0703 alleles and had a high score among all the other epitopes. Only this epitope among the five epitopes reacted with allele 1102 and presented acceptable score for it and other alleles.
The fourth epitope, WVKFHFHTM, covered 22 alleles. It presented a high score in the reaction with alleles as also for the first epitope (1102, 1121 and 1322) and the third epitope (1502); presented high score. It had lower DRB1_0101  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0102  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0301  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0305  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0306  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0307  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0308  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0309  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0311  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0401  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0402  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0404  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0405  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0408  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0410  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0421  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0423  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0426  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0701  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0703  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0801  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0802  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0804  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0806  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0813  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_0817  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1101  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1102  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1104  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1106  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1107  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1114  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1120  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1121  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1128  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1301  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1302  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1304  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1305  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1307  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1311  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1321  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1322  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1323  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1327  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1328  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1501  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1502  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB1_1506  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB5_0101  MVNKDVKQTT  VLLQSTWFL  FHPFDVTKI  DRB5_0105 MVNKDVKQTT VLLQSTWFL FHPFDVTKI Blue region, predicted binders; red color, P1 anchor or the starting residue. 1, % highest score of MVNKDVKQTT; * 1, MVNKDVKQTT is a composition of two epitopes: MVNKDVKQT and VNKDVKQTT. Considered scores were related to epitope that had reaction with MHC or had higher score; 2, % highest score of VLLQSTWFL; 3, % highest score of FHPFDVTKI; 4, % highest score of WVKFHFHTMQ; **4-WVKFHFHTMQ, is a composition of two epitopes: WVKFHFHTM and VKFHFHTMQ. Considered scores were related to epitope that had reaction with MHC or has higher score; 5, % highest score of VKHLTNEEA. Threshold is defined as the 'percentage of best scoring natural peptides'. Threshold setting in this study was 3%. It predicts peptides in catalase sequence which belongs to the 3% best scoring natural peptides; yellow box, high score (1 to 3): the highest score with ranking of 1 to 3 among all of the scores in epitopes of specific and non specific regions; blue box, suitable score for the selected three epitopes; gray box, suitable score for the other two epitopes. 
